ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 16.43% |
2NTRA | NATERA INC | Healthcare | $46.83B | 16.20% |
3INCY | INCYTE CORP | Healthcare | $24.81B | 8.58% |
4GH | GUARDANT HEALTH INC | Healthcare | $20.95B | 7.25% |
5BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 5.27% |
6PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 3.03% |
7TXG | 10X GENOMICS INC | Healthcare | $7.77B | 2.69% |
8AXSM | AXSOME THERAPEUTICS INC | Healthcare | $7.59B | 2.63% |
9IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 2.51% |
10CAI | CARIS LIFE SCIENCES INC | Healthcare | $6.87B | 2.38% |
11KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 2.35% |
12BLLN | BILLIONTOONE INC | Healthcare | $5.29B | 1.83% |
13SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 1.82% |
14LQDA | LIQUIDIA CORP | Healthcare | $5.24B | 1.81% |
15VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 1.22% |
16PBLS | PARABILIS MEDICINES INC | Healthcare | $3.42B | 1.18% |
17WRBY | WARBY PARKER INC | Healthcare | $3.32B | 1.15% |
18AXGN | AXOGEN INC | Healthcare | $3.31B | 1.14% |
19TMDX | TRANSMEDICS GROUP INC | Healthcare | $3.20B | 1.11% |
20DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 1.10% |
21PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.24B | 0.77% |
22REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.72% |
23ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.05B | 0.71% |
24TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Healthcare | $2.05B | 0.71% |
25AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.64% |
26BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.78B | 0.62% |
27NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.59% |
28SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.56% |
29ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 0.54% |
30KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.49% |
31OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.48% |
32TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.37B | 0.47% |
33DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.47% |
34AVLN | AVALYN PHARMA INC | Healthcare | $1.36B | 0.47% |
35PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.35B | 0.47% |
36URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.45% |
37CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.45% |
38INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.45% |
39ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.42% |
40NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.41% |
41SGP | SPYGLASS PHARMA INC | Healthcare | $1.11B | 0.39% |
42MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.10B | 0.38% |
43IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.38% |
44VSTM | VERASTEM INC | Healthcare | $1.06B | 0.37% |
45CTY | CITY THERAPEUTICS INC | Healthcare | $955M | 0.33% |
46OMDA | OMADA HEALTH INC | Healthcare | $912M | 0.32% |
47LTGO | LATIGO BIOTHERAPEUTICS INC | Healthcare | $857M | 0.30% |
48IAM | IAMBIC THERAPEUTICS INC | Healthcare | $703M | 0.24% |
49NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.24% |
50APMD | APNIMED INC | Healthcare | $692M | 0.24% |
51SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $679M | 0.24% |
52CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.22% |
53SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.21% |
54SRZN | SURROZEN INC | Healthcare | $604M | 0.21% |
55IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.20% |
56AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $571M | 0.20% |
57ETRA | ELECTRA THERAPEUTICS INC | Healthcare | $557M | 0.19% |
58CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.18% |
59PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.18% |
60BLSM | BLOSSOMHILL THERAPEUTICS INC | Healthcare | $472M | 0.16% |
61MOBI | MOBIA MEDICAL INC | Healthcare | $444M | 0.15% |
62PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.15% |
63TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.15% |
64FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.13% |
65SCTX | SCRIBE THERAPEUTICS INC | Healthcare | $322M | 0.11% |
66BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.11% |
67CV | CAPSOVISION INC | Healthcare | $314M | 0.11% |
68TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.11% |
69CLPT | CLEARPOINT NEURO INC | Healthcare | $272M | 0.09% |
70QTTB | Q32 BIO INC | Healthcare | $264M | 0.09% |
71ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.08% |
72UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.08% |
73DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.08% |
74GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.08% |
75AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.07% |
76ELMD | ELECTROMED INC | Healthcare | $204M | 0.07% |
77KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.07% |
78ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.06% |
79ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.06% |
80CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.04% |
81SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.04% |
82IMUX | IMMUNIC INC | Healthcare | $106M | 0.04% |
83RTSN | RETENSION PHARMACEUTICALS INC | Healthcare | $97M | 0.03% |
84ICCC | IMMUCELL CORP | Healthcare | $93M | 0.03% |
85RLYB | RALLYBIO CORP | Healthcare | $84M | 0.03% |
86VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.03% |
87NRXS | NEURAXIS INC | Healthcare | $82M | 0.03% |
88NTRB | NUTRIBAND INC | Healthcare | $73M | 0.03% |
89GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.02% |
90XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.02% |
91COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.02% |
92YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.02% |
93ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.02% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $289.06B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 84% toward Large, 78% toward Growth. +17% unclassified (17 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
The constraint checks couldn’t be loaded. The service didn’t respond, so this is a gap in what we could fetch — not a statement about the factor.
Reloading the page usually resolves it.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.68 (fail) but Gaussian VaR gives 1.98 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 15.3% | -0.9% |
| 3 yearsp.a. | 18.2% | 4.0% |
| 5 yearsp.a. | -4.3% | -8.7% |
| 10 yearsp.a. | 0.6% | -8.1% |
| Since inceptionp.a. | -1.1% | -8.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 17.7% | -0.8% |
| 2025 | 33.5% | 20.5% |
| 2024 | -9.5% | -14.1% |
| 2023 | -0.5% | 8.6% |
| 2022 | -33.8% | -26.1% |
| 2021 | -46.9% | -58.1% |
| 2020 | 57.9% | 42.5% |
| 2019 | 24.8% | 2.3% |
| 2018 | -12.6% | -17.8% |
| 2017 | 26.9% | 6.6% |
| 2016 | -16.4% | -9.2% |
| 2015 | 2.1% | -4.3% |
| 2014 | 40.0% | 15.9% |
| 2013 | 43.0% | -4.5% |
| 2012 | 30.9% | 13.3% |
| 2011 | 4.4% | -8.2% |
| 2010 | 17.3% | 9.0% |
| 2009 | 14.1% | -5.8% |
| 2008 | -28.9% | 7.6% |
| 2007 | 1.5% | 1.6% |
| 2006 | 6.1% | 1.8% |
| 2005 | -2.7% | -10.8% |
| 2004 | -0.3% | 0.4% |
| 2003 | 16.6% | -18.9% |
| 2002 | -39.8% | -19.9% |
| 2001 | -29.4% | -13.2% |
| 2000 | -38.1% | -60.7% |
| 1999 | -5.6% | -16.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Tang Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Tang signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.